Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 2
From BugSigDB
Reviewed Marked as Reviewed by Chloe on 2023-12-14
Subjects
- Location of subjects
- Norway
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Inflammatory bowel disease autoimmune bowel disorder,Bowel Diseases, Inflammatory,IBD,INFLAMM BOWEL DIS,inflammatory bowel disease,Inflammatory Bowel Diseases,Inflammatory bowel disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy children
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Non-inflammatory bowel disease symptomatic controls
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- patients under 18 years presented with symptoms of inflammatory bowel disease (Crohn's Disease or ulcerative colitis) but did not meet the criteria for IBD and who had a macroscopically and histologically normal mucosa and normal MRI examination from the catchment areas of two university hospitals in three population-based prospective epidemiological studies of treatment-naïve pediatric IBD in South-Eastern Norway between 2005-2015.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 75
- Group 1 sample size Number of subjects in the case (exposed) group
- 50
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- antibiotics use within the last six months of study for healthy controls (group 0)
Lab analysis
- Sequencing type
- PCR
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- RT-qPCR
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Signature 1
Reviewed Marked as Reviewed by Chloe on 2023-12-14
Source: Table 2
Description: Bacterial species exhibiting deviating abundances between patient and control groups. Non-IBD vs. Healthy.
Abundance in Group 1: decreased abundance in Non-inflammatory bowel disease symptomatic controls
Revision editor(s): Yjung24
Signature 2
Reviewed Marked as Reviewed by Chloe on 2023-12-14
Source: Table 2
Description: Bacterial species exhibiting deviating abundances between patient and control groups. Non-IBD vs. Healthy.
Abundance in Group 1: increased abundance in Non-inflammatory bowel disease symptomatic controls
| NCBI | Quality Control | Links |
|---|---|---|
| Enterococcus faecium | ||
| Citrobacter koseri |
Revision editor(s): Yjung24
